Maximal Exercise Capacity in Chronic Kidney Disease Stage 4-5 Patients Transitioning to Renal Replacement Therapy or Continuing Conservative Care: A Longitudinal Follow-Up Study

被引:3
|
作者
Hellman, Tapio [1 ,2 ]
Lankinen, Roosa [1 ,2 ]
Hakamaeki, Markus [1 ,2 ]
Koivuviita, Niina S. [1 ,2 ]
Paerkkae, Jussi [2 ,3 ]
Kallio, Petri [2 ,3 ,4 ,5 ]
Metsaerinne, Kaj [1 ,2 ]
Jaervisalo, Mikko J. [2 ,6 ,7 ]
机构
[1] Turku Univ Hosp, Kidney Ctr, Turku, Finland
[2] Univ Turku, Turku, Finland
[3] Turku Univ Hosp, Dept Clin Physiol, Turku, Finland
[4] Univ Turku, Paavo Nurmi Ctr, Turku, Finland
[5] Univ Turku, Unit Hlth & Phys Act, Turku, Finland
[6] Turku Univ Hosp, Dept Anaesthesiol & Intens Care, Turku, Finland
[7] Turku Univ Hosp, Dept Intens Care, Turku, Finland
关键词
Chronic kidney disease; Ergometry test; Renal replacement therapy; Exercise capacity; SODIUM-BICARBONATE; PERFORMANCE; ASSOCIATION; SURVIVAL;
D O I
10.1159/000520103
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: Chronic kidney disease (CKD) is associated with impaired maximal exercise capacity (MEC). However, data are scarce on the development of MEC in CKD stage 4-5 patients transitioning to renal replacement therapy (RRT). Methods: We explored the change in MEC measured in watts (Wlast4) with 2 consecutive maximal bicycle stress ergometry tests in 122 CKD stage 4-5 patients transitioning to dialysis and transplantation in an observational follow-up study. Results: Mean age was 58.9 +/- 13.9 years and 43 (35.2%) were female. Mean time between the baseline and follow-up ergometry tests was 1,012 +/- 327 days and 29 (23.8%) patients had not initiated RRT, 50 (41.0%) were undergoing dialysis, and 43 (35.2%) had received a kidney transplant at the time of the follow-up ergometry test. The mean Wlast4 was 91 +/- 37 W and 84 +/- 37 W for the baseline and follow-up ergometry tests, respectively (p < 0.001). The mean Wlast4 declined between the baseline and follow-up ergometry tests in patients not requiring RRT (p = 0.001) and transplant recipients (p = 0.005), but not in dialysis patients (p = 0.478). There were no differences in the ratio of Wlast4 of the follow-up to the baseline ergometry tests ( increment Wlast4) between patients on different treatment modalities at the time of the follow-up test (p = 0.097). Mean capillary blood bicarbonate was significantly associated with increment Wlast4 after adjusting for age and treatment modality in the multivariate linear regression analysis (beta = 0.226, p = 0.012). Conclusion: MEC declined or remained poor in advanced CKD patients transitioning to RRT or continuing conservative care in this observational study. Mean capillary blood bicarbonate was independently associated with the development of MEC.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 50 条
  • [21] Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study
    Baek, Seung Don
    Baek, Chung Hee
    Kim, Ja Seon
    Kim, So Mi
    Kim, Ji Hyun
    Kim, Soon Bae
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2012, 46 (03): : 232 - 238
  • [22] Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis
    Kim, Sang-Hyon
    Lee, So-Yeon
    Kim, Ji-Min
    Son, Chang-Nam
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (04): : 998 - 1003
  • [23] Dental health assessed using panoramic radiograph and adverse events in chronic kidney disease stage 4-5 patients transitioning to dialysis and transplantation-A prospective cohort study
    Jarvisalo, Mikko J.
    Jokihaka, Viljami
    Hakamaki, Markus
    Lankinen, Roosa
    Helin, Heidi
    Koivuviita, Niina S.
    Hellman, Tapio
    Metsarinne, Kaj
    PLOS ONE, 2021, 16 (09):
  • [24] Left atrial appendage occlusion in patients suffering from advanced chronic kidney disease (stage 4 and 5). Long-term follow-up
    Lopez-Tejero, Sergio
    Antunez-Muinos, Pablo
    Fraile-Gomez, Pilar
    Barreira-de Sousa, Gilles
    Rodriguez-Collado, Javier
    Herrero-Garibi, Jesus
    Blanco-Fernandez, Fabian
    Diego-Nieto, Alejandro
    Delgado-Lapeira, Gonzalo C.
    del Villar-Moro, M. Candelas Perez
    Martin-Moreiras, Javier
    Sanchez-Fernandez, Pedro L.
    Cruz-Gonzalez, Ignacio
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2024, 103 (03) : 499 - 510
  • [25] Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
    Lin, Yuan
    Chao, Tze-Fan
    Tsai, Ming-Lung
    Tseng, Chin-Ju
    Wang, Te-Hsiung
    Chang, Chih-Hsiang
    Lin, Yu-Sheng
    Yang, Ning-, I
    Chu, Pao-Hsien
    Hung, Ming-Jui
    Wu, Victor Chien-Chia
    Chen, Tien-Hsing
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (01) : 89 - 100
  • [26] Calprotectin and CRP as biomarkers of cardiovascular disease risk in patients with chronic kidney disease: a follow-up study at 5 and 10 years
    Lofblad, Lena
    Hov, Gunhild Garmo
    asberg, Arne
    Videm, Vibeke
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (04): : 258 - 263
  • [27] Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study
    Khan, Yusra Habib
    Sarriff, Azmi
    Adnan, Azreen Syazril
    Khan, Amer Hayat
    Mallhi, Tauqeer Hussain
    Jummaat, Fauziah
    NEPHROLOGY, 2017, 22 (01) : 25 - 34
  • [28] Stabilization of glomerular filtration rate in advanced chronic kidney disease: A two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5
    Serrano, Andres
    Huang, Jie
    Ghossein, Cybele
    Nishi, Laura
    Gangavathi, Anupama
    Madhan, Vijayachitra
    Ramadugu, Paramesh
    Ahya, Shubhada N.
    Paparello, James
    Khosla, Neenoo
    Schlueter, William
    Batlle, Daniel
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2007, 14 (01) : 105 - 112
  • [29] NT-proBNP in the Prognosis of Death or Need for Renal Replacement Therapy in Patients with Stage 3-5 Chronic Kidney Disease
    Gromadzinski, Leszek
    Januszko-Giergielewicz, Beata
    Czarnacka, Kamila
    Pruszczyk, Piotr
    CARDIORENAL MEDICINE, 2019, 9 (02) : 125 - 134
  • [30] Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson’s disease: longitudinal follow-up study on previously untreated patients
    Jan Rusz
    Tereza Tykalová
    Jiří Klempíř
    Roman Čmejla
    Evžen Růžička
    Journal of Neural Transmission, 2016, 123 : 379 - 387